Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Cancer Immunotherapy: Dana-Farber has licensed a large patent portfolio covering PD-1 and PD-L1 to multiple pharmaceutical companies
Acetylon Pharmaceuticals, a Dana-Farber start-up company, has launched Regenacy Pharmaceuticals, as Celgene Corporation acquires Acetylon
Myles Brown, MD, director of our Center for Functional Cancer Epigenetics, has been elected to The National Academy of Sciences
C4 Therapeutics, a successful Dana-Farber start-up company, is harnessing the innate power of the body to control the quality of proteins within cells
In the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI), our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through collaborations and relationships with industry.
As a bridge between research and industry, BODFI is committed to building relationships with companies both large and small, with the investor community, and with entrepreneurs. Our goal is to create solutions.
At BODFI, we will: Work with you to license Dana-Farber technologies Facilitate your interactions with Dana-Farber's researchers, research centers, and core facilities Create novel collaboration structures to accommodate your evolving needs Coordinate with you to start new companies based on Dana-Farber innovations Expedite all necessary confidentiality, material transfer, or other agreements for the above
At BODFI, we will:
Technology News Study of Rare Ovarian Cancer Sheds Light on Epigenetic Cancer Process Using a rare, lethal form of ovarian cancer as a lens, scientists at Dana-Farber Cancer Institute have discovered how the loss of two key, enzymatic parts of a gene-regulating protein complex in cells can drive them into malignant growth. Investigators led by Cigall Kadoch, PhD, found that when two components that serve as the “engines” of the SWI/SNF chromatin remodeling complex are both mutated – as they invariably are in the rare ovarian cancer type known as SCCOHT– genes that are normally expressed in the healthy ovary are shut off, and genes that allow the cell cycle to run unchecked are turned on. Unusual Mechanism of CDK4/6 Inhibitor Resistance Found, May Be Reversible Breast cancer cells can acquire resistance to the relatively new drugs known as CDK4/6 inhibitors by producing higher amounts of CDK6, a cell cycle protein, a new study has found, and those cells can transfer their resistant traits to other cancer cells via molecular carriers called exosomes. This drug resistance mechanism, identified by researchers at Dana-Farber Cancer Institute, is highly unusual, they said, and laboratory studies suggest it may be reversible. Breast cancer cells that developed resistance to a CDK4/6 inhibitor, palbociclib, became sensitive to the drug again after a “treatment holiday” of several weeks when no palbociclib was administered, they said in an article in Cell Reports.
Using a rare, lethal form of ovarian cancer as a lens, scientists at Dana-Farber Cancer Institute have discovered how the loss of two key, enzymatic parts of a gene-regulating protein complex in cells can drive them into malignant growth.
Investigators led by Cigall Kadoch, PhD, found that when two components that serve as the “engines” of the SWI/SNF chromatin remodeling complex are both mutated – as they invariably are in the rare ovarian cancer type known as SCCOHT– genes that are normally expressed in the healthy ovary are shut off, and genes that allow the cell cycle to run unchecked are turned on.
Breast cancer cells can acquire resistance to the relatively new drugs known as CDK4/6 inhibitors by producing higher amounts of CDK6, a cell cycle protein, a new study has found, and those cells can transfer their resistant traits to other cancer cells via molecular carriers called exosomes.
This drug resistance mechanism, identified by researchers at Dana-Farber Cancer Institute, is highly unusual, they said, and laboratory studies suggest it may be reversible. Breast cancer cells that developed resistance to a CDK4/6 inhibitor, palbociclib, became sensitive to the drug again after a “treatment holiday” of several weeks when no palbociclib was administered, they said in an article in Cell Reports.
General: innovation@dfci.harvard.eduAcademic MTAs: mta@dfci.harvard.edu
• Six Collaboration Agreements with Various Pharmaceutical and Research Companies
• Two Sponsored Research Agreements with Pharmaceutical Companies
• One Material Evaluation with a Biotechnology Start-Up Company